UBS Group’s CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) CYNA Stock Holding History

UBS Group’s Portfolio CYNA Stock Details CYNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,437	Closed	-$460K	–	8410
2016 Q3	$460K	Buy	11,437 +10,737	+1,534%	+$265K	﹤0.01%	3970
2016 Q2	$12K	Sell	700 -26	-4%	-$350	﹤0.01%	6704
2016 Q1	$9K	Buy	+726	New	+$9.72K	﹤0.01%	6755
2015 Q4	–	Sell	-1,147	Closed	-$19K	–	8797
2015 Q3	$19K	Sell	1,147 -1,006	-47%	-$16.3K	﹤0.01%	6780
2015 Q2	$35K	Buy	+2,153	New	+$35.3K	﹤0.01%	6351

UBS Group's CYNA Position: Q4 2016 in Review

UBS Group sold out of CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) (CYNA) in Q4 2016, closing a stake of 11,437 shares — an estimated $460K sold.

UBS Group first reported a position in CYNA in Q2 2015 and held it in 5 quarters. The position peaked at $460K in Q3 2016. 0 funds tracked by Wall St. Rank hold CYNA as of Q4 2016.

UBS Group reported no remaining CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position as of Q4 2016 after selling out during the quarter.
UBS Group sold 11,437 CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) shares in Q4 2016, an estimated $460K.
UBS Group first reported a position in CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q2 2015 and held it in 5 quarters.
UBS Group's CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position peaked at $460K in Q3 2016.
0 funds tracked by Wall St. Rank held CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.